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Abstract
Pharmacogenetic (PGx) testing aims to improve therapeutic outcomes through tailoring treatment
based on a patient’s genetic risk for non-response and/or an adverse event. Given their expertise,
geneticists could facilitate the use of PGx testing; however, , the preparedness and perceived role
of the clinical genetics community is unclear. To assess the attitudes, preparedness, and perceived
roles of geneticists in the delivery of PGx testing, we conducted a survey of 1500 randomly
selected board-certified genetic counselors and clinical geneticists in the U.S (response rate:
37.8% (n=516)). Twelve percent of genetic counselors and 41% of clinical geneticists indicated
that they had ordered or coordinated patient care for PGx testing, a seemingly high proportion at
this early stage of adoption. Almost all respondents had some education on pharmacogenetics,
though only 28% of counselors and 58% of clinical geneticists indicated they felt well-informed
about PGx testing. About half of counselors (52%) and clinical geneticists (46%) felt they would
play ‘some’ role in the delivery of PGx testing; 17% and 19%, respectively, felt that they would
play ‘no’ or ‘a little’ role. At this early stage of PGx testing, the role of geneticists and genetic
counselors is unclear. However, their experience may aid in readying PGx testing and informing
delivery strategies into clinical practice.
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INTRODUCTION
Drug developers and health professionals have long been aware of the heterogeneity in drug
response, often due to a combination of factors associated with disease type, co-morbidities,
poly-pharmacy and unique patient characteristics. Several genetic variations associated with
adverse responses or likelihood to respond have been identified (1), yielding a new group of
clinical tests known as pharmacogenetic (PGx) tests aimed to improve drug treatment
outcomes (2,3). The wide range of drugs that now include information in the labels about the
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effects of genetic variation on treatment outcome or risk of adverse response (4)
demonstrates the rapid growth of the field and applicability across multiple medical
specialties.
Despite advances in pharmacogenetics, the translation of these new tests to clinical practice
is variable (5). The slower uptake may be due to unfamiliarity about the appropriate use of
these tests, lack of robust evidence of clinical utility or recommendations for test use,
concerns about reimbursement, ethical concerns and unfamiliarity with genetic testing in
general (6–12). The use of PGx testing is also unclear with respect to issues of informed
consent and the storage and portability of test results.
While any prescribing clinician may order a PGx test, the use of PGx testing currently
appears to be limited to experts of a particular drug target or disease (5, 13–14). The role of
other medical specialists, namely geneticists and pharmacists, is unclear. While clinical
genetic laboratorians and researchers may be involved in the development of PGx tests,
including the discovery and link to a drug-related phenotype, it is unclear what role
geneticists and genetic counselors may play, if any, in the delivery of PGx testing in clinical
care. Given their knowledge and experience in the provision, counseling and interpretation
of genetic testing for disease diagnosis and prediction, geneticists and genetic counselors
would appear to be a valuable resource in guiding the use of these tests, which are based on
inherited variants that often have implications for more than one drug and may potentially
imply disease risks as well (15).
No research has been conducted to ascertain geneticists and genetic counselors’ attitudes
and their role regarding the delivery of PGx tests. Therefore, we conducted a survey to
assess their experience with and training about PGx testing and views on issues related to
the delivery of PGx tests. This includes views on the appropriate roles for geneticists,
genetic counselors and other health professionals, informed consent, and reporting results.
These data can help identify potential challenges of translating PGx testing into clinical




The survey was developed through a collaborative effort between investigators at Duke
University’s Institute for Genome Sciences & Policy and the Survey Research Unit at the
University of North Carolina, Chapel Hill. The survey questions were based on a literature
review, data collected from three groups of health professionals including geneticists and
genetic counselors (11), and a legal analysis of managing incidental findings from PGx
testing. The reporting of geneticist attitudes towards PGx testing with incidental findings
will be published separately.
Survey Pre-testing
To evaluate understandability and the ability of respondents to complete the questions as
intended, a panel of clinical geneticists and genetic counselors pre-tested the survey through
an online evaluation noting confusing questions and ambiguous terms and reporting
confidence in answering questions accurately. The resulting survey was comprised of 7
major parts, totaling 101 questions: 1) demographics; 2) background information on clinical
practice; 3) knowledge of PGx testing and preferred educational sources; 4) experience with
PGx testing; 5) attitudes towards determining clinical value of a PGx test; 6) provider
preferences and practices with incidental risk information revealed by a PGx test; and 7)
provider preferences, actions, decisions and obligations regarding PGx testing with and
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without incidental information. The majority of questions used a 5-point Likert scale to
assess levels of likelihood, interest or, agreement with certain statements.
Sampling methods
A total of 1,500 names were randomly selected from the population of genetic counselors
(n=1,946) and clinical geneticists (n=1,053) obtained from the American Board of Genetic
Counselors and the American Board of Medical Genetics, respectively (750 per group). The
only available information on the frames were names, addresses, and phone numbers. The
samples were stratified by census regions to ensure representation from the midwest,
northeast, south and west. The lists were compared to delete duplicate listings of individuals
with membership in both groups. Our response rates, 45.2% for counselors and 31.2% for
clinicians, were calculated based on standards set by the American Association for Public
Opinion Research. An overall response rate of 37.8% was achieved for a total of 516
completed surveys, 846 non-responses, and 138 ineligibles (e.g., retired, no longer
practicing).
Data Collection
The survey was conducted from June 15 to October 31, 2010. The mode of data collection
included an online web survey, mail questionnaire, or fax (if requested). A mailed letter of
support from the President of the National Society of Genetic Counselors (E. Kearney) or
the Executive Director of the American College of Medical Genetics (M. Watson) was sent
with the invitation along with the URL for the online survey. Approximately two weeks
later, the survey instrument was sent with a postage-paid return envelope and instructions on
how to access the survey website to those who did not complete the online survey in the first
request. If an email address was available, we followed up by email instead. All
communications were personalized and included a unique access code for purposes of
follow-up and logging into the online survey. This study was approved by the Institutional
Review Boards at Duke University Medical Center and the University of North Carolina,
Chapel Hill. Survey respondents were eligible to enter a drawing for an Apple iPad and
received a $25 Amazon gift card.
Data Analysis
Sample weights were produced as the inverse of stratum-specific sampling rates and then
adjusted for differential non-response in the sample based on census region response rates. It
was not possible, however, to post-stratify the sample based on demographic characteristics
of the population such as race, age or gender because we did not have access to such data.
Therefore, we were not able to correct for any demographic differences and potential biases
that might exist. The following estimates were weighted and a 95% confidence bound was
provided where applicable. Cochran-Mantel-Haenszel (CMH) Chi-square tests were
conducted, adjusting for gender and race when comparing the two groups (genetic
counselors and clinical geneticists) on a binary response. All analyses were conducted in
SUDAAN (Version 10.0, 2008; Research Triangle Institute International, Research Triangle




A total of 516 complete eligible responses were received. Overall, respondents were 76%
female (±2.72%) and self-identified as White (90%) (± 2.37%). Fifty-eight percent were
board-certified in genetic counseling; 43% were board-certified in clinical genetics. There
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was a significant difference in year of graduation with more than half (53%) of genetic
counselors receiving their Master’s degree after 2000, compared to 64% of clinical
geneticists who received their medical degree before 1991 (χ2 = 62.07, p < 0.0001). (See
Table 1)
Training & Experience with PGx Testing
Ninety percent of genetic counselors indicated that they had some education relating to
pharmacogenetics: 36% (±5.10) indicated that they had learned about pharmacogenetics
through graduate school courses and 53% (±5.29%) had learned about pharmacogenetics
from the literature, seminars, professional meetings, or representatives of testing
laboratories. In comparison, 96% of clinical geneticists indicated that they had some
education regarding pharmacogenetics, with 18% (±4.43%) learning about
pharmacogenetics in medical school and 78% (±4.80%) beyond medical school. Year of
graduation was positively associated with learning about PGx through graduate coursework
(χ2 = 24.12, p < 0.001).
Twenty-eight percent (±4.63%) of genetic counselors indicated that they strongly or
somewhat strongly agreed that they felt well-informed about PGx testing compared to 58%
(±5.80) of clinical geneticists. Overall, there was a significant association between feeling
well-informed and having PGx-related coursework (χ2=24.11, p<0.0001). However, there
was no significant association found between year of graduation and likelihood of feeling
well-informed about PGx testing (genetic counselors: (χ2 = 1.49, p = 0.2044; clinical
geneticists: χ2 = 0.75, p = 0.5618). Fifty-nine percent of clinical geneticists indicated that
they would feel or felt comfortable ordering a PGx test, which was strongly associated with
feeling well-informed about PGx testing (χ2=20.53, p<0.0001). Similarly, 42% (± 5.23%)
of genetic counselors indicated that they would feel or felt comfortable counseling a patient
about PGx testing, which was strongly associated with feeling well-informed (χ2=54.15,
p<0.0001).
Regarding actual practices in ordering or coordinating patient care for PGx testing, 12%
(±3.53) of genetic counselors indicated that they had ordered or coordinated patient care for
PGx testing 1–10 times per year. For clinical geneticists, 35% (±5.68) had ordered PGx
testing 1–10 times per year and 6% (±2.86) more than 10 times per year. Respondents who
had graduated prior to 1991 were more likely to order PGx tests than those who had
graduated after 2000 (χ2 = 3.73, p = 0.0058) as were those who felt well-informed
compared to those who did not feel well-informed (χ2 = 7.08, p < 0.0001).
Perceived Roles in Delivery of PGx Testing
About half of genetic counselors (52% ±5.44%) and clinical geneticists (46%; ±5.98%) felt
they would play ‘some’ part in the delivery of PGx testing; 17% (±4.06%) and 19%
(±4.78%), respectively, felt that they would play no role or ‘a little’ role. When asked which
health professional or group should have primary responsibility for various steps in the
delivery of PGx testing, more than half of genetic counselors and clinical geneticists
believed that a disease specialist had primary responsibility to inform the patient about the
availability of PGx testing, discuss the PGx test results with the patient, and determine how
the PGx test result should inform drug selection and/or dosing (Table 2). Both genetic
counselors (45.2%) and clinical geneticists (49.5%) believed that a record of the patient’s
PGx test results should be maintained through the primary care practitioner. However, a
substantial proportion of genetic counselors (40.5%) and clinical geneticists (39.6%)
indicated that they should have a primary role in discussing PGx results with the patient.
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Important Factors Regarding Use of PGx Testing
We asked respondents to indicate the importance of 13 potential test characteristics or
related factors regarding the clinical use of a PGx test to predict an adverse drug reaction
(Table 3). For four of the factors, more than half of respondents considered them to be
important with respect to clinical use of the test to predict an adverse drug reaction: severity
of the drug reaction, prevalence of the drug reaction, predictive value of the test, and
availability of guidelines for test use/interpretation. There was a statistically significant
difference in the proportion of genetic counselors (35% ±5.08%) and clinical geneticists
(44% ±5.90%) who felt that the prevalence of the genetic variant was a very important
factor (p=0.0179). A significantly greater proportion of genetic counselors (64.0% ±5.12%)
versus clinical geneticists (53.1% ±5.90) felt that availability of practice guidelines for test
use and interpretation was a very important factor (p=0.0062).
For PGx tests to predict drug response, more than half of genetic counselors and clinical
geneticists indicated five of 13 factors were important: prevalence of non-response to the
drug, predictive value of the test, urgency of treatment, severity of condition being treated,
and availability of guidelines for test use/interpretation. The perceived importance for
several factors significantly varied between the two groups including urgency of treatment
(p=0.0363), inclusion of information about the test on the drug label (p=0.0324), and
availability of an alternative drug (p=0.0002).
Informed Consent and Counseling—Fifty-two percent (±6.13%) of genetic counselors
and 54% (±6.25%) of clinical geneticists believed that genetic counseling would be
necessary. In addition, the majority of genetic counselors (67%; ±5.68) indicated that written
informed consent should be obtained prior to PGx testing, though significantly fewer clinical
geneticists (39% ±5.98%) agreed that it should (χ2 = 11.44, p = 0.0008).
Reporting & Storage of PGx test results—When asked about their preference for the
reporting format, most genetic counselors (98.7% ±1.18%) and clinical geneticists (96.0%
±2.27) agreed that the test report should contain both test result (e.g., genotype) and
phenotype regarding drug safety or efficacy.
Regarding the storage of PGx test results, significantly more clinical geneticists (80.2%
±4.76%) than genetic counselors (73.2% ± 4.68%) strongly agreed that PGx test results
should be stored in a patient’s medical record (p=0.036). A smaller proportion of genetic
counselors (58.8% ± 5.17%) and clinical geneticists (62.6% ±5.72%) strongly agreed that
results should be stored in a patient’s pharmacy record. Clinical geneticists were
significantly more likely to indicate that PGx test results should be stored in both a patient’s
medical and pharmacy record (70.5% ±5.41% vs. 60.3% ±5.10%) (p=0.0089). Most genetic
counselors (81.8% ±4.06%) and clinical geneticists (78.9% ±4.82%) also strongly agreed
that patients should keep a copy of PGx test results to aid prescribing by different treating
physicians.
DISCUSSION
Although use of PGx testing is not yet widespread, consideration of the role of specialists at
this early stage will help facilitate the transition to broader use and minimization of potential
harms. Geneticists already play some role in overseeing the development and performance
of PGx testing as laboratory directors, but their role with respect to clinical delivery and
counseling remains to be explored. We find that geneticists and genetic counselors appear
unclear about their role at this early stage of test use. About half believe that they will play
some part in the delivery of PGx testing, with 40% of respondents believing they should
have a primary role in discussing PGx test results with patients.
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We found 12% of genetic counselors and 41% of clinical geneticists indicated that they had
ordered or coordinated patient care for PGx testing, a seemingly high proportion at this early
stage of adoption. Further study of the types of tests ordered by geneticists may clarify
whether their experience was a result of referrals or the incorporation of new testing for
patients traditionally treated by geneticists. High use of PGx testing by other medical
specialists has been reported (12–14), suggesting their comfort in ordering PGx testing
without involvement of a geneticist or genetic counselor.
The combination of differing comfort levels, education, and relationships with patients may
have attributed to several differences in responses observed between genetic counselors and
clinical geneticists. For example, almost twice as many counselors indicated that written
informed consent was necessary for PGx testing compared to clinical geneticists. This
difference in opinion may be attributed to counselors’ training, which emphasizes
exploration of psychosocial issues as well as facilitation of informed decision-making (16).
Support of written informed consent might also reflect a recognition that geneticists are not
likely to be involved in the delivery of PGx testing and it could help assure that non-genetics
professionals discuss pertinent issues with patients. The relatively large proportion of
respondents supportive of written informed consent, however, contrasts with previous
reports that consent is not routinely obtained for PGx testing (17, 18), though other data
suggests that clinicians would seek to obtain consent (19). The perceived importance of
informed consent as well as counseling for PGx testing among geneticists, particularly
counselors, may also reflect current practices with disease-based testing.
This is the first study to explore the views and attitudes of geneticists and genetic counselors
regarding PGx testing, however, some limitations should be noted. Although the sample was
randomly drawn from the population of board-certified genetic counselors and clinical
geneticists, those familiar with PGx testing may have been more likely to respond to the
survey, resulting in response bias and limiting the generalizability of the findings. We were
not able to correct for any demographic differences and potential biases that might exist. In
addition, responses to hypothetical clinical scenarios may not account for complexities in
actual clinical practice and the differences in practice between genetic counselors and
clinical geneticists (e.g., with respect to test ordering).
At this early stage, the clinical integration of PGx testing will likely benefit from a
collaborative approach to facilitate the safe and appropriate use of PGx testing. Specifically,
geneticists may serve as a useful resource to prescribing clinicians, providing expertise on
test characteristics and interpretation of results, as many clinicians may have little
knowledge about pharmacogenetics or genetics in general. However, with respect to actual
delivery of testing, the time-sensitive nature of drug treatment would seem to preclude pre-
testing consultation with geneticists. The prescribing physician and/or primary care clinician
would appear to be the optimal place for integration of PGx testing to maximize both
immediate and long-term benefits of testing over a patient’s lifetime. Another possibility
would be pharmacists as they also advise on drug-drug interactions and related issues to
optimize drug response and minimize risk of adverse effects. Future studies should assess
the need for and feasibility of consulting genetic specialists in the delivery of PGx testing in
various clinical specialties and testing scenarios.
While interpretation and communication may be well within the expertise of geneticists, the
reporting, storage and management of pharmacogenetic information is not limited to
geneticists and warrants broad consideration to inform practice guidelines. This is
particularly germane as testing platforms have moved away from single gene-based testing
to panel testing and eventually to whole genome sequencing, resulting in the generation of
more prevalent and complex information. Thus, consultation with geneticists on genome
Haga et al. Page 6













analysis or interpretation may increase until general clinician knowledge increases and/or
new tools are developed to aid in patient genome queries.
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Table 1
Demographic characteristics of survey respondents expressed as weighted percentages (standard errors in
parentheses).
Demographic Characteristics Genetic Counselors (n=295) Clinical Geneticists (n=218) Combined (n=516)
Weighted % (SE) Weighted %(SE) Weighted %(SE)
Female 97 (0.93) 48 (3.02) 76 (1.39)
Race
White 90 (1.61) 84 (2.22) 88 (1.32)
Non-White
 Black/African-American 1 (0.45) 2 (0.96) 1 (0.48)
 Asian 4 (1.06) 6 (1.5) 5 (0.88)
 Other 5 (1.19) 7 (1.58) 6 (0.96)
Hispanic 2 (0.81) 4 (1.18) 3 (0.69)
Year of Graduation (from genetic counseling
program or medical school)
Before 1980 1 (0.64) 29 (2.71) 13 (1.22)
1981–1990 12 (1.74) 35 (2.86) 22 (1.58)
1991–2000 34 (2.57) 26 (2.61) 30 (1.85)
After 2000 53 (2.69) 10 (1.83) 35 (1.73)
Primary Practice Location
 Community-based or hospital-affiliated 6 (1.29) 5 (1.39) 6 (0.95)
 Hospital-based 18 (2.07) 8 (1.63) 14 (1.37)
 Academic Medical Center 54 (2.69) 69 (2.72) 60 (1.93)
 Private practice 8 (1.50) 7 (1.56) 8 (1.09)
 Private testing laboratory 5 (1.15) 1 (0.57) 4 (0.70)
 Government 1 (0.71) 2 (0.70) 2 (0.47)
 HMO 1 (0.65) 2 (0.87) 2 (0.52)
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